Merck KGaA And Sanofi-Aventis To Co-Develop Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
In a rare early-stage R&D collaboration, two Big Pharmas will evaluate novel combinations of signaling-pathway anticancers.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases
FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.